File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevention and management of hepatitis B virus reactivation in cancer patients

TitlePrevention and management of hepatitis B virus reactivation in cancer patients
Authors
KeywordsHBV
Anti-HBc
HBsAg
HSCT
Rituximab
Cancer
Issue Date2016
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072
Citation
Hepatology International, 2016, v. 10 n. 3, p. 407-414 How to Cite?
AbstractHepatitis B virus (HBV) reactivation during immunosuppressive therapy is common in patients with solid tumor or hematological malignancies. It is associated with significant morbidity and mortality due to hepatitis flare and/or hepatic decompensation. These consequences arising from HBV reactivation are, however, largely preventable. Routine screening for HBV serologic status is recommended for all cancer patients undergoing chemotherapy or biologics. By recognizing different serological patterns (which represent either overt or occult HBV infection) and the types of immunosuppressive therapies prescribed, a risk-adapted approach can be established. Prophylactic therapy with nucleos(t)ide analogues (prior to or concomitantly with the commencement of immunosuppressive therapies) is more effective than pre-emptive therapy (starting antiviral when HBV DNA level is rising) in high-risk individuals. Entecavir has been proven to be more effective than lamivudine according to recent studies. Close monitoring of serum HBV level is the preferred strategy in low-risk patients. However, the optimal interval of DNA monitoring and the duration of therapy remain unknown.
Persistent Identifierhttp://hdl.handle.net/10722/226356
ISSN
2023 Impact Factor: 5.9
2023 SCImago Journal Rankings: 1.813
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, KSM-
dc.contributor.authorSeto, WKW-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2016-06-17T07:43:35Z-
dc.date.available2016-06-17T07:43:35Z-
dc.date.issued2016-
dc.identifier.citationHepatology International, 2016, v. 10 n. 3, p. 407-414-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/226356-
dc.description.abstractHepatitis B virus (HBV) reactivation during immunosuppressive therapy is common in patients with solid tumor or hematological malignancies. It is associated with significant morbidity and mortality due to hepatitis flare and/or hepatic decompensation. These consequences arising from HBV reactivation are, however, largely preventable. Routine screening for HBV serologic status is recommended for all cancer patients undergoing chemotherapy or biologics. By recognizing different serological patterns (which represent either overt or occult HBV infection) and the types of immunosuppressive therapies prescribed, a risk-adapted approach can be established. Prophylactic therapy with nucleos(t)ide analogues (prior to or concomitantly with the commencement of immunosuppressive therapies) is more effective than pre-emptive therapy (starting antiviral when HBV DNA level is rising) in high-risk individuals. Entecavir has been proven to be more effective than lamivudine according to recent studies. Close monitoring of serum HBV level is the preferred strategy in low-risk patients. However, the optimal interval of DNA monitoring and the duration of therapy remain unknown.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072-
dc.relation.ispartofHepatology International-
dc.subjectHBV-
dc.subjectAnti-HBc-
dc.subjectHBsAg-
dc.subjectHSCT-
dc.subjectRituximab-
dc.subjectCancer-
dc.titlePrevention and management of hepatitis B virus reactivation in cancer patients-
dc.typeArticle-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12072-015-9692-3-
dc.identifier.pmid26739135-
dc.identifier.scopuseid_2-s2.0-84953214296-
dc.identifier.hkuros258633-
dc.identifier.hkuros302532-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spage407-
dc.identifier.epage414-
dc.identifier.isiWOS:000373595200004-
dc.publisher.placeUnited States-
dc.identifier.issnl1936-0533-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats